Oncotarget

Research Papers:

The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence

Weilin Xu, Liansheng Gao, Anwen Shao, Jingwei Zheng and Jianmin Zhang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:91030-91039. https://doi.org/10.18632/oncotarget.19024

Metrics: PDF 2327 views  |   HTML 2923 views  |   ?  


Abstract

Weilin Xu1,*, Liansheng Gao1,*, Anwen Shao1,*, Jingwei Zheng1 and Jianmin Zhang1,2,3

1Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

2Brain Research Institute, Zhejiang University, Hangzhou, Zhejiang, China

3Collaborative Innovation Center for Brain Science, Zhejiang University, Hangzhou, Zhejiang, China

*These authors have contributed equally to this work as co-first authors

Correspondence to:

Jianmin Zhang, email: [email protected]

Keywords: methionine, PET, glioma, recurrence, meta-analysis

Received: April 28, 2017     Accepted: June 20, 2017     Published: July 05, 2017

ABSTRACT

Despite the advancement of neuroimaging techniques, it often remains a diagnostic challenge to distinguish recurrent glioma from lesions representing treatment effect. Preliminary reports suggest that 11C-methionine Positron emission tomography (PET) can assist in diagnosing true glioma recurrence. We present here a meta-analysis to assess the accuracy of 11C-methionine PET in identifying recurrent glioma in patients who had undergone prior therapy. A comprehensive search of the PubMed, Embase and Chinese Biomedical (CBM) databases yielded 23 eligible articles comprising 29 studies listed prior to November 20, 2016, representing 891 patients. In this report, we assess the methodological quality of each article individually and perform a meta-analysis to obtain the summary diagnostic accuracy of 11C-methionine PET in correctly identifying recurrent glioma. The pooled sensitivity and specificity are 0.88 (95% CI: 0.85, 0.91) and 0.85 (95% CI: 0.80, 0.89), respectively, with an area under the curve (AUC) for the summary receiver-operating characteristic curve (SROC) of 0.9352. We conclude that 11C-methionine PET has excellent diagnostic performance for differentiating glioma recurrence from treatment effect.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19024